Trial Profile
A Phase 1-2, First-in-Human Study of CX-2029 in Adults With Metastatic or Locally Advanced Unresectable Solid Tumors or Diffuse Large B-cell Lymphomas (PROCLAIM-CX-2029)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 29 Jan 2024
Price :
$35
*
At a glance
- Drugs CX-2029 (Primary)
- Indications Adenocarcinoma; Carcinoma; Colorectal cancer; Diffuse large B cell lymphoma; Endometrial cancer; Gastric cancer; Head and neck cancer; Liver cancer; Malignant melanoma; Malignant thymoma; Mesothelioma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Parotid cancer; Perivascular epithelioid cell tumours; Soft tissue sarcoma; Solid tumours; Squamous cell cancer; Thymoma; Thyroid cancer
- Focus Adverse reactions; First in man
- Acronyms PROCLAIM-CX-2009-001; PROCLAIM-CX-2029
- Sponsors CytomX Therapeutics
- 22 Jan 2024 Status changed from active, no longer recruiting to completed.
- 22 Feb 2023 Planned End Date changed from 1 Dec 2022 to 30 Apr 2023.
- 22 Feb 2023 Planned primary completion date changed from 1 Dec 2022 to 30 Apr 2023.